|1.||Ranson, Marie: 5 articles (03/2015 - 07/2004)|
|2.||Buduneli, Nurcan: 5 articles (02/2011 - 07/2004)|
|3.||Kardeşler, Levent: 4 articles (02/2011 - 04/2005)|
|4.||Vrhovec, I: 4 articles (04/2003 - 01/2001)|
|5.||Varro, Andrea: 3 articles (01/2013 - 07/2002)|
|6.||Dimaline, Rod: 3 articles (01/2013 - 07/2002)|
|7.||Lappin, David: 3 articles (02/2011 - 07/2004)|
|8.||Schmitt, M: 3 articles (08/2005 - 02/2000)|
|9.||Kinnby, Bertil: 3 articles (09/2004 - 01/2002)|
|10.||Borstnar, S: 3 articles (04/2003 - 04/2002)|
03/01/2015 - "However, PAI-2 is rapidly cleared via the renal system which impairs tumor uptake and efficacy. "
01/20/2002 - "Previous studies including various tumor types have shown different associations between tumor tissue levels of plasminogen activator inhibitor 2 (PAI-2) and patient survival. "
03/01/2013 - "In addition, positive PAI-2 staining was related to smaller tumor size and prolonged patient survival. "
03/01/2013 - "Positive PAI-2 staining was observed in tumor and non-tumor tissues from 21 (26.9%) and 56 (71.8%) patients, respectively. "
01/01/2009 - "Since overexpression of uPA at the surface of cancer cells is linked to malignancy, targeting of uPA by exogenous recombinant PAI-2 has been proposed as the basis of potential cancer therapies. "
|2.||Neoplasm Metastasis (Metastasis)
12/19/1997 - "PAI-2 expression in the metastases of invasive stages III and IV cases was strongly predictive of a prolonged disease-free and overall survival. "
03/01/2007 - "Among them, PAI-2 and DRHC were confirmed to be upregulated with real-time PCR and Western blot, suggesting a possible association with PEDF-induced signaling for cell motility and metastasis. "
02/01/2003 - "Multivariate analysis revealed that four independent prognostic factors for overall survival time were uPA, PAI-2, lymph node metastasis and recurrences and clinical stage, P = 0.001, 0.002, 0.035 and 0.005 respectively. "
09/01/2000 - "For metastasis-free survival, uPA index (p = 0.006) and PAI-2 index (p = 0.04) were independent prognostic factors. "
02/01/1999 - "However, only PAI-2 reduced the incidence of lung and brain metastasis following liver gene transfer. "
07/01/2004 - "In CsA GO+ sites t-PA levels were significantly elevated in comparison with gingivitis and healthy sites, while PAI-2 levels in these sites showed statistically significant differences only with CsA-H and gingivitis sites (p<0.05). "
07/01/2004 - "The levels of t-PA and PAI-2 were significantly higher in CsA GO- sites compared with those of CsA-H, gingivitis and healthy sites (p<0.05). "
05/01/1996 - "The lower inhibitory capacity in terms of a low production of PAI-2 during pregnancy in women with a higher inflammatory reaction indicates that the components of the fibrinolytic system may be involved in the development of pregnancy gingivitis and implies that PAI-2 serves as an inhibitor of importance for tissue proteolysis. "
03/01/2000 - "In the present study, the levels of t-PA and PAI-2 in gingival crevicular fluid (GCF) were measured from healthy, gingivitis and periodontitis sites and compared before and after periodontal treatment. "
04/01/2005 - "Gingivitis and periodontitis patients had higher GCF concentrations of PAI-2 than healthy subjects (p<0.002 and p<0.02 respectively). "
|4.||Varicose Ulcer (Ulcer, Venous)
08/01/2000 - "Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study."
08/01/2000 - "These findings suggest that regulation of protease activity by u-PA and PAI-2 may play a role in the impaired healing of chronic venous ulcers."
08/01/2000 - "PAI-2 levels were significantly higher in the ulcer edge and base in the healing wounds than in chronic venous ulcers (P<0.05). "
08/01/2000 - "The concentrations of functional u-PA, u-PA antigen and PAI-1 were significantly greater and PAI-2 was significantly lower in the edge and base of chronic venous ulcers compared to adjacent intact skin (P<0.01). "
08/01/2000 - "The concentrations of u-PA, t-PA, PAI-1 and PAI-2 antigen as well as functional u-PA were assessed in tissue homogenates from 20 chronic venous ulcers, six actively healing venous ulcers and five traumatic wounds. "
06/01/1991 - "Serial serum PAI-2 determinations in 16 patients with acute leukemia at presentation, during therapy, remission, and relapse revealed that in the five patients with M4-M5, elevated PAI-2 levels rapidly normalized under therapy and during remission, but increased again in the patients with a relapse associated with an M4-M5 phenotype. "
08/01/1991 - "PL-21 is a promyelocytic leukemia cell line that produces plasminogen activator inhibitor 2 (PAI-2). "
06/01/1991 - "Thus, PAI-2 seems to be a marker highly specific for the active stages of monocytic leukemia, i.e. "
06/01/1991 - "PAI-2 was detected in plasma and leukemic cells of the 21 patients with leukemia having a monocytic component [acute myelomonocytic (M4), acute monoblastic (M5), and chronic myelomonocytic leukemias], and in the three patients with acute undifferentiated myeloblastic leukemia (M0). "
05/01/1991 - "PAI-2 antigen was demonstrated in the cell lysates of various leukemia cells by Western blotting technique using a monoclonal antibody against the PAI-2 purified from PL-21 culture medium. "
|1.||Plasminogen Activator Inhibitor 1
|2.||Urokinase-Type Plasminogen Activator (Urokinase)
|3.||Plasminogen Activators (Plasminogen Activator)
|5.||Tissue Plasminogen Activator (Alteplase)
|7.||Urokinase Plasminogen Activator Receptors
|8.||Messenger RNA (mRNA)
|5.||Heterologous Transplantation (Xenotransplantation)